Phase 2 Study Comparing Antiviral Treatments for Early Symptomatic Respiratory Syncytial Virus in Adults Aged 18 to Under 65

What this Trial Is About

Researchers are evaluating antiviral treatments for Respiratory Syncytial Virus RSV in low-risk adults aged 18 to under 65 years with early symptoms. This adaptive, open-label, randomized platform trial compares licensed and potential antiviral drugs against no treatment to assess their antiviral effects in patients with high viral loads and uncomplicated RSV infections. The study is funded by the Wellcome Trust and led by the University of Oxford. Participants will be randomly assigned to receive one of several antiviral drugs or no antiviral treatment. The study drugs include oral ribavirin, dosed based on weight three times daily for 5 days molnupiravir, given twice daily for 5 days and favipiravir, with a higher dose on Day 0 followed by a lower dose twice daily for 4 more days. The control group will receive supportive care without antiviral drugs. The trial maintains a minimum 20% allocation to no-treatment control throughout its duration. Participants will be involved for 28 days, during which researchers will measure the rate of viral clearance from Days 0 to 5, assess symptom relief and fever duration up to Day 14, and monitor for possible drug resistance. Evaluations include rapid antigen or PCR tests for RSV, symptom reporting, and clinical assessments. The study also tracks safety and antiviral effects, with follow-up visits planned to monitor progress and outcomes.

Assessing Antiviral Treatments in Early Symptomatic RSV